Search results
The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Clovis Oncology, Inc. (NASDAQ:CLVS) shareholders, with the analysts...
What Kind Of Shareholders Own Clovis Oncology, Inc. (NASDAQ:CLVS)?
Simply Wall St. via Yahoo Finance· 2 years agoIf you want to know who really controls Clovis Oncology, Inc. (NASDAQ:CLVS), then you'll have to...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 1 year agoClovis Oncology (NASDAQ:CLVS) Third Quarter 2022 ResultsKey Financial Results Revenue: US$30.7m...
Cancer Focused Clovis Oncology Files For Bankruptcy
Benzinga via Yahoo Finance· 1 year agoClovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets...
Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation...
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd signed a clinical supply...
Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on...
Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) announced topline data from the Phase 3 TRITON3 trial,...
Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) announced a presentation detailing initial Phase 1 data from...
Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line...
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) announced results from a subgroup analysis from the Phase 3...